EXEL · Nasdaq · CIK 0000939767
EXELIXIS, INC.
EXELIXIS, INC.’s most recent SEC filing in our snapshot is a Form 8-K filed on Sep 11, 2026. In fiscal 2026 (year ended Jan 2, 2026) it reported revenue of $2.3B and net income of $782.6M, according to its XBRL data on EDGAR. Its EDGAR record lists 53 Form 4 insider filings from the 12 months before our last refresh.
SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.
Company overview
- Legal name (as filed)
- EXELIXIS, INC.
- Ticker
- EXEL
- SEC Central Index Key (CIK)
- 0000939767
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (code 2836)
- Business address
- ALAMEDA, CA
- State or country of incorporation
- DE
- Fiscal year ends
- January 1
- SEC filer category
- Large accelerated filer
- Position in SEC ticker list
- #669 of the 3,000 companies we track
Five-year financial highlights
Full-year figures from EXELIXIS, INC.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.
| Item | FY2021 ended Dec 31, 2021 | FY2022 ended Dec 30, 2022 | FY2023 ended Dec 29, 2023 | FY2025 ended Jan 3, 2025 | FY2026 ended Jan 2, 2026 |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.6B | $1.8B | $2.2B | $2.3B |
| Net income | $231.1M | $182.3M | $207.8M | $521.3M | $782.6M |
| Diluted EPS | $0.72 | $0.56 | $0.65 | $1.76 | $2.78 |
| Total assets | $2.6B | $3.1B | $2.9B | $2.9B | $2.8B |
| Cash and equivalents | $647.2M | $501.2M | $263.0M | $217.4M | $482.5M |
XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.
How to read these numbers
Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.
Advertisement
Latest key reports
The most recent filing of each major report type, even if it falls outside the 40 newest filings below.
| Filed | Form | What it is | Original |
|---|---|---|---|
| Feb 10, 2026 | 10-K | Annual report· period Jan 2, 2026 | Document · Index |
| Aug 5, 2026 | 10-Q | Quarterly report· period Jul 3, 2026 | Document · Index |
| Sep 11, 2026 | 8-K | Other events· period Sep 10, 2026 | Document · Index |
| Apr 15, 2026 | DEF 14A | DEFA14A· period May 26, 2026 | Document · Index |
Recent SEC filings
The 40 newest documents filed by or about EXELIXIS, INC., by form type:
| Filed | Form | What it is | Original |
|---|---|---|---|
| Sep 11, 2026 | 8-K | Other events· period Sep 10, 2026 | Document · Index |
| Aug 31, 2026 | 8-K | Other events· period Aug 31, 2026 | Document · Index |
| Aug 14, 2026 | SCHEDULE 13D/A | Active beneficial ownership report (over 5%) | Document · Index |
| Aug 12, 2026 | SCHEDULE 13G/A | Passive beneficial ownership report (over 5%) | Document · Index |
| Aug 12, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026 | Document · Index |
| Aug 10, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Aug 5, 2026 | S-8 | Registration of employee benefit plan securities | Document · Index |
| Aug 5, 2026 | 10-Q | Quarterly report· period Jul 3, 2026 | Document · Index |
| Aug 5, 2026 | 8-K | Results of operations· period Aug 5, 2026 | Document · Index |
| Jun 3, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 1, 2026 | Document · Index |
| Jun 3, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 1, 2026 | Document · Index |
| Jun 1, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Jun 1, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| May 29, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 27, 2026 | Document · Index |
| May 29, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 27, 2026 | Document · Index |
| May 29, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 27, 2026 | Document · Index |
| May 29, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 27, 2026 | Document · Index |
| May 29, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 27, 2026 | Document · Index |
| May 29, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 27, 2026 | Document · Index |
| May 29, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 27, 2026 | Document · Index |
| May 29, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 27, 2026 | Document · Index |
| May 29, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 27, 2026 | Document · Index |
| May 29, 2026 | 8-K | Director or officer change; Shareholder vote results· period May 26, 2026 | Document · Index |
| May 29, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 27, 2026 | Document · Index |
| May 28, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 26, 2026 | Document · Index |
| May 26, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| May 22, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 20, 2026 | Document · Index |
| May 20, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| May 19, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 15, 2026 | Document · Index |
| May 19, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 15, 2026 | Document · Index |
| May 19, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 15, 2026 | Document · Index |
| May 19, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 15, 2026 | Document · Index |
| May 19, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 15, 2026 | Document · Index |
| May 18, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| May 18, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| May 14, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| May 8, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 7, 2026 | Document · Index |
| May 8, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 7, 2026 | Document · Index |
| May 8, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 7, 2026 | Document · Index |
| May 8, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 6, 2026 | Document · Index |
Insider filing activity
53 Form 4 filings appear in EXELIXIS, INC.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.
Advertisement
Other companies in Biological Products, (No Diagnostic Substances)
- AMGN AMGEN INC
- GILD GILEAD SCIENCES, INC.
- MRNA Moderna, Inc.
- ARGX ARGENX SE
- RVMD Revolution Medicines, Inc.
- BIIB BIOGEN INC.
- BNTX BioNTech SE
- NBIX NEUROCRINE BIOSCIENCES INC
All 61 companies in Biological Products, (No Diagnostic Substances)· Companies headquartered in California
On Amazon
Popular tools for investors
As an Amazon Associate I earn from qualifying purchases.
Source
- U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0000939767 and XBRL company facts. EXELIXIS, INC. on EDGAR.
- Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.
Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.
Advertisement